.. 199-9 (150 to 268) 195-7 (156 to 235) Standard weight (lb.) ..
138-2 (123 to 153)
139-1 (123 to 153) Initial excess weight (%) .. 44-7 (22 to 91) 40-8 (22 to 81) Weight change (lb.) .. At the beginning of the trial all subjects were told how and why it was going to be conducted. No alteration was made to the diet they were then supposed to be taking, and they were asked to come to a special clinic every two weeks wearing as nearly as possible the same clothing. At each visit the patient was weighed, was asked if she had noted any symptoms which she attributed to the tablets, and was given a further two weeks' supply of tablets, the nature of which was not known to either her or the doctor.
Patients in one group were given tablets containing 20 mg. of fenfluramine hydrochloride, and those in the other group inert tablets identical in appearance, taste, and consistency with the active preparation. All took two tablets half to one hour before the main meal of the day and one tablet before each of two other meals, except a few patients who ate only two meals a day, who took two tablets before each of them. At the end of the study the pharmaceutical company supplying the tablets revealed which were the active and which the inert ones.
Results
Five patients in each group did not complete the trial. Of those taking fenfluramine one never took the tablets, two stopped taking them because of diarrhoea, and two became pregnant. Four taking the dummy tablets defaulted for reasons that could not be ascertained, and another stopped the tablets because she was gaining weight and considered them " useless." Table I shows that at the end of the 12-weeks study the mean weight change of patients taking fenfluramine was 9.3 lb. (-4,220 g.) and of those taking the dummy 0.4 lb. (+ 180 g.); this difference is statistically highly significant (P<0.001). Moreover, all those taking fenfluramine lost weight, whereas in the group taking the dummy 10 lost, 14 gained, and 1 was unchanged in weight.
The Figure shows that the mean weight of the patients taking. fenfluramine continued to decrease during the 12-weeks period, although the mean weight loss in each fortnightly period was becoming less, being -2.8, -1.6, -1.8, -1.2, -1.5, and -0.5 lb. (-1,270, -725, -815, -545, -680, and -225 g.) for each of the successive periods. The apparent reduction in effect of fenfluramine is less pronounced if the mean weight loss of those taking fenfluramine is compared with the mean weight change of those taking the dummy, the differences in each succeeding fortnightly period being 1.8, 1.8, 1.9, 1.4, -1.5, and -1.3 lb (-815, -815, -860, -635, -680 , and 590 g.) respectively. However, because of the wide variation in weight loss between individuals in both groups it is not possible to determine statistically whether or not this represents a significant falling off in the weight-reducing effect of the drug. The subjective effects reported by patients and thought by them to be due to the tablets are set out in Table II . Diarrhoea was the most common, occurring in 10 patients taking fenfluraamine. Two of these stopped taking the tablet because of it, one of them passing more than 20 loose motions in the day; diarrhoea recurred in both when they started taking the fenfluramine again. Five patients taking the inert tablets also said they had some diarrhoea, but in none was it severe. 
Discussion
Earlier studies on the value of fenfluramine as an appetitedepressant were encouraging. Traherne (1965) reported a mean weight loss of 7.0 lb. (3,175 g.) in patients taking fenfluramine for 12 weeks, compared with a loss of 2.3 lb. (1,040 g.) in those given placebo tablets; Duncan et al. (1965) found that patients given fenfluramine for four weeks, lost, on average, 8.9 lb. (4,040 g.), whereas those taking a placebo lost 4.4 lb. (1,995 g.) .
In both studies, however, patients were instructed in a lowcalorie diet at the start of the study, which makes it difficult to assess the effect of the drug.
The present investigation was carried out on patients with "refractory obesity." Such subjects provide a severe test for an appetite-depressant, but one which is valuable because they form a fairly standard group and are also those most in need of an effective aid to dieting. In an attempt to eliminate the influence of dietary change the patients were asked to make no deliberate alteration in their dietary habits ; that this was effective is suggested by the poor response of those taking the inert tablets.
The mean weight loss of 9.3 lb. (4,220 g.) in 12 weeks which occurred in the patients taking the fenfluramine is greater than that obtained in trials of comparable duration in similar patients having refractory obesity using phenmetrazine (Duncan et al., 1960) , diethylpropion (Seaton et al., 1961) , chlorphentermine (Seaton et al., 1964a) , and dexamphetamine and phentermine (Seaton et al., 1964b) , in which the mean weight loss varied from 2.6 lb. (1,180 g.) with diethylpropion to 6.3 lb. (2,860 g.) with dexamphetamine. Moreover, whereas all the above preparations had clearly lost their appetite-suppressant effect in the majority of patients within 12 weeks, no such tolerance to the drug was demonstrated with fenfluramine. However, a longer study than that reported here would be required to demonstrate if and when fenfluramine loses its appetitedepressant effect. Thus fenfluramine, although expensive, appears to be a more effective appetite-suppressant than the other anorectic drugs that we have so far tested.
However, a mean weight loss of only 9.3 lb. (4,220 g.) in 12 weeks is still not very substantial, though it does represent a mean reduction in food intake of about 300 calories a day from that which would have kept the patient's weight steady.
Side-effects were not particularly troublesome, although diarrhoea occurred in 10 of the 25 patients taking fenfluramine, being severe in two. Evidence of C.N.S. stimulation was not obtained in the present study, and the drug has previously been shown to have no hypertensive action (Le Douarec and Schmitt, 1964; Lambusier, 1965 ).
Summary
The appetite-depressant action of fenfluramine was evaluated against an inert tablet by a 12-weeks double-blind trial in 60 women having " refractory obesity "; 50 patients completed the trial. The mean weight change after 12 weeks was -9.3 lb. (-4,220 g.) in those taking fenfluramine, whereas in those given dummy tablets it was +0.4 lb. (+0.180 g.) .
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